The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Biomarker analysis of a phase II trial of cabozantinib and erlotinib in patients (pts) with EGFR-mutant NSCLC with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance: A California Cancer Consortium Phase II Trial (NCI 9303).
 
Karen L. Reckamp
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb
Research Funding - ARIAD; Astellas Pharma; Bristol-Myers Squibb; Celgene; Clovis Oncology; Eisai; Gilead Sciences; GlaxoSmithKline; Novartis; Pfizer; Xcovery
 
Philip C. Mack
Research Funding - Boehringer Ingelheim
 
Nora Ruel
No Relationships to Disclose
 
Paul Henry Frankel
No Relationships to Disclose
 
Barbara J. Gitlitz
Speakers' Bureau - Genentech; Lilly
Travel, Accommodations, Expenses - Genentech; Lilly
 
Tianhong Li
Speakers' Bureau - Pfizer
Research Funding - Astellas Pharma (Inst); Lilly (Inst); Novartis (Inst)
 
Marianna Koczywas
No Relationships to Disclose
 
Shirish M. Gadgeel
Consulting or Advisory Role - Genentech
 
Mihaela C. Cristea
No Relationships to Disclose
 
Chandra Prakash Belani
No Relationships to Disclose
 
Edward M. Newman
No Relationships to Disclose
 
David R. Gandara
Honoraria - Array BioPharma; AstraZeneca; Celgene; Lilly; Novartis; Synta
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech; GlaxoSmithKline; Lilly; Merck; Novartis; Pfizer; Response Genetics; Sanofi; Synta
Research Funding - Abbott Laboratories (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); ImClone Systems (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Biomarin; Boehringer Ingelheim; Dava Oncology; Pfizer
 
Primo Lara
Honoraria - Pfizer
Consulting or Advisory Role - Astex Pharmaceuticals; Clovis Oncology; Exelixis; Halozyme; Immunogen; Janssen; Lilly; LPath; Medivation; Novartis; Pfizer; Sanofi; Teva; US Diagnostic Services
Research Funding - Aragon Pharmaceuticals (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Heat Biologics (Inst); Janssen Biotech (Inst); Millennium (Inst); Oncogenex (Inst); Polaris (Inst)